Research programme: docetaxel oral - Athenex

Drug Profile

Research programme: docetaxel oral - Athenex

Alternative Names: Docetaxel + HM-30181A; Oradoxel; Oral docetaxel - Athenex

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Athenex
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Aug 2016 Athenex plans a phase I trial for Prostate cancer (Metastatic disease) in New Zealand (ACTRN12616000983404)
  • 26 Jan 2016 The US FDA approves IND application for oradoxel in cancer
  • 15 Dec 2015 Athenex plans a phase I trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top